A Compliant Abbott Channels More Funds Into Core Diagnostics R&D
This article was originally published in The Gray Sheet
Executive Summary
Now that Abbott is in the final throes of a 1999 FDA consent degree, the company's core chemistry and immunoassay diagnostics unit says it has freed up some more funds for research and development
You may also be interested in...
FDA Panel Recommends New Studies For Fujirebio’s Ovarian Cancer Test
FDA should not clear Fujirebio's HE4 enzyme immunoassay kit and associated "risk of ovarian malignancy algorithm"(ROMA) until the firm demonstrates the test's ability to help community physicians triage patients for referral to gynecologic oncology specialists, according to the agency's Immunology Devices advisory panel
Abbott’s Recommitment To Core Diagnostics Is Rewarded By Strong Returns
Abbott has a newfound loyalty to its long-struggling core diagnostics business, which the company was at the brink of unloading just last year, and the division has responded with a dramatic turnaround
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.